|
| Study | Available treatment modality | Available hormonotherapy drugs | Outcome |
|
| Diallo et al. [8] | Surgical ADT (76.3%), medical ADT (22.4%) | Cyproterone acetate | 8% castrate resistant |
| Botcho et al. [9] | Surgical ADT (38.6%), medical ADT, both (18.9%) | Cyproterone acetate, flutamide, LHRH analogue, chemotherapy | |
| Tengue et al. [12] | Surgical ADT (34.5%), medical ADT (12.5%), both (46.1%) | Cyproterone acetate, flutamide | 15.1% mortality |
| Kirakoya et al. [10] | Surgical ADT (24.3%), medical ADT (62.2%), both (13.4%) | Cyproterone acetate, LHRH analogue | 10.9% mortality |
| Kaboré et al. [14] | Surgical ADT (43.3%), medical ADT (19%), both (9.5%) | Cyproterone acetate, LHRH analogue | |
| Wasike and Magoha [15] | Mostly surgical ADT, few medical ADT | Low-dose stilboestrol | |
| Badmus et al. [19] | Surgical ADT (71.9%), medical ADT (24.3%), both (22.2%) | Stilboestrol, bicalutamide, goserelin, flutamide | 5-year overall survival (7.4%) |
| Yeboah et al. [21] | Neoadjuvant hormonotherapy ± medical ADT, EBRT, brachytherapy, TUIP, TURP | Docetaxel, LHRH analogue, stilboestrol, bicalutamide /flutamide | 11% hospital mortality |
| Ekwere and Egbe [13] | Surgical ADT and medical ADT | Stilboestrol | 0% 5-year overall survival |
| Konan et al. [22] | Surgical ADT (86.2%), medical ADT (13.7%) | Cyproterone acetate, LHRH analogue | 16.2% mortality |
| Sow et al. [23] | Group 1: surgical ADT and medical ADT only
Group 2: cytoreductive therapy + castration | | Group 1: 6-month median (OS)
Group 2: 8-month median (OS) |
|
